In our Brief Report the following data required correction: In Table 1, in the platinum-pemetrexed plus pembrolizumab column, the number of patient alive and who died of a disease related death have been corrected to 5 (26%) and 11 (58%) respectively as shown below In Figure 1D, the number of patients at risk at 48 months for pembrolizumab has been corrected to 4 as shown below. [Table presented][Formula presented]
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]"
Ciardiello, Fortunato;
2024
Abstract
In our Brief Report the following data required correction: In Table 1, in the platinum-pemetrexed plus pembrolizumab column, the number of patient alive and who died of a disease related death have been corrected to 5 (26%) and 11 (58%) respectively as shown below In Figure 1D, the number of patients at risk at 48 months for pembrolizumab has been corrected to 4 as shown below. [Table presented][Formula presented]File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
